calcipotriol/betamethasone dipropionate / Generic mfg. |
| Completed | 3 | 1485 | Canada, Europe | Calcipotriol plus betamethasone dipropionate (LEO80185 gel) | LEO Pharma | Psoriasis of Scalp | | 09/05 | | |
| Completed | 3 | 1350 | Canada, Europe | Calcipotriol plus betamethasone dipropionate (LEO80185 gel) | LEO Pharma | Psoriasis of Scalp | | 09/05 | | |
| Completed | 3 | 300 | Canada, Europe | Calcipotriol plus betamethasone dipropionate (LEO80185 gel) | LEO Pharma | Psoriasis of Scalp | | 05/06 | | |
| Completed | 3 | 800 | Canada, Europe | Calcipotriol plus betamethasone dipropionate gel (LEO 80185) | LEO Pharma | Psoriasis of Scalp | | 07/06 | | |
NCT00279162: Efficacy and Safety of Calcipotriene/Betamethasone Gel/Ointment in Psoriasis |
|
|
| Completed | 3 | 160 | US | Calcipotriene/betamethasone gel and ointment | LEO Pharma | Psoriasis | | 07/07 | | |
BELIEVE, NCT00574249 / 2007-003073-97: Adalimumab in Combination With Topical Treatment (Calcipotriol/Betamethasone) in Subjects With Moderate to Severe Psoriasis and Insufficient Response to Classic Systemic Treatment |
|
|
| Completed | 3 | 730 | Europe, RoW | adalimumab, ABT-D2E7, Humira, Calcipotriol/Betamethasone Ointment, Daivobet, placebo (vehicle ointment) | Abbott | Chronic Plaque Psoriasis | 10/08 | | | |
|
|
|
|
NCT00670241: Efficacy and Safety of Calcipotriol Plus Betamethasone Dipropionate Gel Compared With Tacalcitol Ointment and the Gel Vehicle Alone in Patients With Psoriasis Vulgaris |
|
|
| Completed | 3 | 458 | Canada | calcipotriol and betamethasone (LEO 80185 gel), LEO 80185 vehicle, Tacalcitol ointment | LEO Pharma | Psoriasis Vulgaris | 02/09 | 04/09 | | |
NCT01195831: Efficacy and Safety of Xamiol® Gel Compared to Calcipotriol Scalp Solution in Patients With Scalp Psoriasis |
|
|
| Completed | 3 | 244 | RoW | Xamiol® gel, Calcipotriol scalp solution | LEO Pharma | Scalp Psoriasis | 03/11 | 03/11 | | |
NCT01188928: LEO 80185 in the Treatment of Psoriasis Vulgaris on the Non-scalp Regions of the Body (Trunk and/or Limbs) |
|
|
| Completed | 3 | 1152 | US | Calcipotriol plus betamethasone, Betamethasone-17,21-dipropionate, Calcipotriene, Topical suspension vehicle | LEO Pharma | Psoriasis Vulgaris | 03/11 | 03/11 | | |
|
|
|
NCT01422434: LEO 90105 Ointment in Japanese Subjects With Psoriasis |
|
|
| Completed | 3 | 676 | Japan | LEO 90105 = calcipotriol + betamethasone dipropionate, LEO 90105 = Dovobet/Daivobet/Taclonex, Dovonex® = calcipotriol, Rinderon® - DP = betamethasone dipropionate | LEO Pharma, Quintiles, Inc. | Psoriasis | 04/12 | 04/12 | | |
NCT02132936 / 2013-004686-14: LEO 90100 Aerosol Foam Compared to Calcipotriol Plus Betamethasone Dipropionate Gel in Subjects With Psoriasis Vulgaris |
|
|
| Completed | 3 | 504 | Europe | LEO 90100 aerosol foam, Aerosol foam vehicle, Calcipotriol BDP gel, Gel vehicle | LEO Pharma | Psoriasis Vulgaris | 02/15 | 02/15 | | |
|
|
| Completed | 3 | 219 | Canada | LEO 90100 Aerosol Foam, Daivobet® gel | LEO Pharma | Psoriasis Vulgaris | 07/15 | 07/15 | | |
NCT02668692: LEO 80185 Gel (Calcipotriol Hydrate Plus Betamethasone Dipropionate) in Japanese Subjects With Psoriasis |
|
|
| Completed | 3 | 213 | Japan | LEO 80185 gel, Dovobet ® ointment | LEO Pharma, CMIC Co, Ltd. Japan | Psoriasis Vulgaris | 06/16 | 06/16 | | |
2016-001106-42: Clinical study to compare two gels with the active substance calcipotriol and betamethasone and one gel without active substance for patients with scalp psoriasis |
|
|
| Completed | 3 | 225 | Europe | Calcipotriol 50 µg/g_Betamethasone 0.5 mg/g Gel, Daivobet 50 Mikrogramm/g + 0.5 mg/g Gel, Gel, Daivobet(R) 50 Mikrogramm/g + 0,5 mg/g Gel | Dermapharm AG, Dermapharm AG | Psoriasis capitis, Psoriasis of scalp, Diseases [C] - Skin and Connective Tissue Diseases [C17] | | | | |
| Completed | 3 | 411 | Europe | calcipotriol-betamethasone, Daivobet®, TEST, REFERENCE, Ointment, Daivobet® | Dermapharm AG, Dermapharm AG | chronic stable plaque psoriasis, Psoriasis vulgaris, Diseases [C] - Skin and Connective Tissue Diseases [C17] | | | | |
NCT03331523: To Study Generic Calcipotriene and Betamethasone Dipropionate Topical Suspension, 0.005%/0.064%, in the Treatment of Scalp Psoriasis |
|
|
| Completed | 3 | 643 | US | Calcipotriene/Betamethasone Dipropionate, Taclonex®, Placebo | Glenmark Pharmaceuticals Ltd. India | Scalp Psoriasis | 10/18 | 10/18 | | |
2018-002532-24: A study to demonstrate that topical treatment with the generic calcipotriol- betamethasone gel is therapeutically equivalent to the originator Daivobet® gel in the treatment of chronic stable, mild to moderate plaque-type psoriasis |
|
|
| Ongoing | 3 | 280 | Europe | Calcipotriol 50 μg/g_Betamethasone 0.5 mg/g, Gel, Daivobet® | HELM AG, Helm AG | mild to moderate plaque-type psoriasis, mild to moderate psoriasis, Diseases [C] - Skin and Connective Tissue Diseases [C17] | | | | |
NCT05919082: A Study to Investigate Efficacy and Safety With LEO 90100 Compared With Daivobet® Ointment in Adult Chinese Subjects With Stable Plaque Psoriasis |
|
|
| Completed | 3 | 604 | RoW | LEO 90100, Daivobet® ointment | LEO Pharma | Stable Plaque Psoriasis | 02/24 | 03/24 | | |